NCT03080974

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: University of Louisville · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Detailed description

Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab post-operatively.

Conditions

• Pancreatic Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Nivolumab	Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
PROCEDURE	Irreversible Electroporation	Non-thermal ablation of tumor

Timeline

• Start date: 2017-08-14
• Primary completion: 2028-06-01
• Completion: 2029-04-01
• First posted: 2017-03-15
• Last updated: 2025-10-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study